Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 19/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 19/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028925 | 1.00 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4027814 | 0.91 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4034189 | 0.90 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4034192 | 0.90 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4028102 | 0.89 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4028103 | 0.89 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5162265 | 0.88 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4025227 | 0.86 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4025224 | 0.86 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4030231 | 0.84 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562588-A4 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | claimed |
| EP-1633306-A4 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-05-16 | — | — | EP | claimed |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | MERCK & CO., INC. | 2006-11-16 | — | — | US | claimed |
| US-20060069115-A1 | Use of pde4 inhibitors as adjunct therapy for psychiatric disorders | SCOLNICK EDWARD M | 2006-03-30 | — | — | US | claimed |
| EP-1633306-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | MERCK FROSST CANADA LTD. (CA) | 2006-02-23 | — | — | US | claimed |
| EP-1592419-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | Merck Frosst Canada & Co. (CA) | 2005-11-09 | — | — | EP | claimed |
| EP-1562588-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004105698-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | claimed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | claimed |
| WO-2004045508-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-06-03 | — | — | WO | claimed |
| EP-1244628-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | claimed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | claimed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | claimed |
| WO-2001046151-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | claimed |
| EP-1363635-B1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-1562588-A4 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | disclosed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | disclosed |
| WO-2001046151-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20060258668-A1 | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders | PPP3CA, PTPA, PPP3CB | PDE4A 253/4885PDE4B 268/4885PDE4C 303/4885 |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.